Optimization of immunologic testing

‘Made-in-Canada’ assays perform well to measure seroprevalence

Despite the many assays available to test for SARS-CoV-2 antibodies, a gold standard has not yet been established. In an article now published in PLOS ONE, CITF Testing Working Group members Dr. Anne-Claude Gingras from the University of Toronto, and Dr. Steven Drews from Canadian Blood Services, evaluate multiple testing platforms and the concordance between test results in this CITF-funded study. P

2022-04-19T10:29:38-04:00October 5, 2021|Optimization of immunologic testing|
Go to Top